Global Coalition for Adaptive Research (GCAR) is a 501(c)3 nonprofit organization committed to developing and sponsoring Master Protocols and Adaptive Platform Trials to speed the discovery of treatments for patients with rare and deadly diseases.
GLIOBLASTOMA
Survival rates of GBM patients is less than 5% within 5 years of diagnosis
OVARIAN CANCER
Women with BRCA1 gene mutation have a 45% lifetime risk of ovarian cancer; BRCA2 mutation = 25% risk
COVID-19
95% of those affected by COVID-19 report immediate and long-term health issues
Global Coalition for Adaptive Research (GCAR), Sponsor of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) master protocol, announced that regorafenib has completed enrollment and follow-up in GBM AGILE.
The Global Coalition for Adaptive Research (GCAR) in collaboration with Biohaven and Vigeo Therapeutics, today announced the activation of Biohaven’s troriluzole and Vigeo’s VT1021 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment).
Global Coalition for Adaptive Research, the U.S. Sponsor of REMAP-COVID, announced that Eisai has ended the evaluation of eritoran in the REMAP-COVID study.